Search

Search Constraints

You searched for: Author/Creator Shusterman, Suzanne

Search Results

1. Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease. Issue 15 (6th June 2022)

2. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Issue 10 (8th April 2022)

3. Evaluation of the utility of 99mTc‐MDP bone scintigraphy versus MIBG scintigraphy and cross‐sectional imaging for staging patients with neuroblastoma. Issue 11 (27th April 2017)

5. HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS. (4th December 2020)

7. PDCT-13. ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS. (11th November 2019)

8. Phase 1 evaluation of EZN‐2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Issue 10 (24th June 2014)

9. Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Issue 11 (12th August 2021)

10. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. Issue 3 (7th October 2022)